Metonitazene Stats & Data
CCN(CC)CCn1c(Cc2ccc(OC)cc2)nc2cc(ccc12)N(=O)=OHNGZTLMRQTVPBH-UHFFFAOYSA-NEffect Profile
Curated + 2 ReportsStrong euphoria, itching/nausea, and pain relief with moderate sedation
Tolerance & Pharmacokinetics
drugs.wikiCross-Tolerances
Experience Report Analysis
ErowidDemographics
Gender Distribution
Age Distribution
Reports Over Time
Harm Reduction
drugs.wikiPotency estimates for metonitazene vary by source and matrix; drug checking data has described it as roughly fentanyl-strength in some periods and up to ~4× fentanyl in others, underscoring high uncertainty across batches. It has increasingly appeared as an adulterant in samples not expected to contain high‑potency opioids (e.g., counterfeit oxycodone/“Percocet”, hydromorphone, and even cocaine/other non‑opioids), so assume unknown powders or pressed pills may contain a nitazene. Nitazenes, including metonitazene, are frequently found with other depressants such as benzodiazepine‑related drugs and veterinary tranquilizers (xylazine, medetomidine), which dramatically increase the risk of life‑threatening respiratory depression. Naloxone reverses nitazene overdoses but multiple sequential doses are often required; continue to administer naloxone every 2–3 minutes until breathing improves and emergency help arrives. Because fentanyl test strips do not detect nitazenes, a negative FTS result does not rule them out; some jurisdictions now distribute nitazene‑specific strips, but availability and sensitivity vary. Due to sub‑milligram potency and uneven distribution in powders, never eyeball; if handling any powder, use an accurate milligram scale and volumetric dilution to reduce hot‑spot risk. Avoid using alone; ensure someone can monitor breathing, place the person in the recovery position if unresponsive, and call emergency services promptly at the first sign of overdose (slow/absent breathing, cyanosis, unresponsiveness). Avoid combining with any sedatives (alcohol, benzos, gabapentinoids) and beware that stimulants can mask overdose signs without reducing respiratory depression. Metonitazene’s half‑life in humans is not well-established; observe for re‑sedation (“re‑narcotization”) after naloxone and seek medical monitoring. Not clinically approved for medical use; first identified in the unregulated drug supply around 2021 and subsequently implicated in fatalities in multiple countries.
References
Drugs.wiki References
- Toronto Drug Checking Service – Nitazene opioids (overview and relative strength)
- Toronto Drug Checking Service – Report (Oct 18–31, 2025): nitazenes incl. metonitazene, and naloxone notes
- Toronto Drug Checking Service – Report (Dec 16–29, 2023): co-occurrence with benzos/xylazine; nitazenes in fentanyl supply
- Toronto Drug Checking Service – Historical report (Jul 31–Aug 13, 2021): nitazenes present in expected fentanyl/heroin samples
- Toronto Drug Checking Service – Report (Apr 9–22, 2022): nitazenes and co-depressants in overdose-associated samples
- Hi‑Ground nitazenes HR resource – FTS do not detect nitazenes; detection challenges
- Saferparty.ch – Nitazene page (in German): higher naloxone administrations vs fentanyl; extreme potency and Safer Use
- EUDA (EU drug agency) – 2024 highlights: nitazenes in fake meds; mixtures with benzos/xylazine; under-detection
- EUDA European Drug Report 2024 – nitazenes already associated with harms/outbreaks; mis-sold as heroin; mixtures
- PubChem – Metonitazene compound entry (identifiers)
- Pharmacological characterization: metonitazene as a potent μ-opioid receptor agonist (in vitro/in vivo) – PubMed